SCHEMBL15599045

SCHEMBL15599045

O[C@H]1[C@H](F)[C@@H](O)CN[C@@H]1CF

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GANAB Q14697 3/20 0.69
GAA P10253 6/20 0.45
MGAM O43451 4/20 0.45
AGL P35573 3/20 0.45
SI P14410 3/20 0.45
GLA P06280 3/20 0.45
PYGL P06737 2/20 0.45
MAN1B1 Q9UKM7 2/20 0.45
GBA2 Q9HCG7 3/20 0.43
FUCA1 P04066 3/20 0.43
MEN1 O00255 2/20 0.43
ALOX15 P16050 2/20 0.43
KMT2A Q03164 2/20 0.43
GBA1 P04062 2/20 0.43
LCT P09848 2/20 0.43
GBA3 Q9H227 2/20 0.43
MAN2B1 O00754 1/20 0.43
MAN2B2 Q9Y2E5 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18730394 1.00 GANAB (0.69) GANABGAAMGAMAGLSI
SCHEMBL15598970 0.83 GAA (0.68) GANABGAAMGAMAGLSI
SCHEMBL15599039 0.82 GANAB (1.00) GANABGAAMGAMAGLSI
SCHEMBL29471360 0.82 GANAB (1.00) GANABGAAMGAMAGLSI
SCHEMBL14119813 0.65 GANAB (0.64) GANABGAAMGAMAGLSI
SCHEMBL6857345 0.65 GANAB (0.64) GANABGAAMGAMAGLSI
SCHEMBL6857322 0.65 GANAB (0.64) GANABGAAMGAMAGLSI
SCHEMBL8892109 0.62 GANAB (0.54) GANABGAAMGAMAGLSI
Iminoribitol SCHEMBL981088 0.62
Iminoribitol SCHEMBL3365896 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170107180-A1 GLYCOSIDASE INHIBITORS AND USES THEREOF MERCK SHARP & DOHME CORP. 2017-04-20 US disclosed
US-20170107180-A1 GLYCOSIDASE INHIBITORS AND USES THEREOF MERCK SHARP & DOHME CORP. 2017-04-20 US disclosed
US-20150299122-A1 GLYCOSIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2015-10-22 US disclosed
US-20150299122-A1 GLYCOSIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2015-10-22 US disclosed
WO-2014032184-A1 GLYCOSIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299122-A1 GLYCOSIDASE INHIBITORS AND USES THEREOF OGA, ENGASE, OGT GANAB 56/4885GAA 6/4885MGAM 40/4885
US-20170107180-A1 GLYCOSIDASE INHIBITORS AND USES THEREOF OGA, ENGASE, OGT GANAB 56/4885GAA 6/4885MGAM 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.